Furthermore, Su et al. [72] indicated that Gal-1 inhibition enhanced the sensitivity of the hepatocellular carcinoma cells toward cisplatin and augmented its anti-tumor activity. The gene discussed is LGALS1; the disease is hepatocellular carcinoma.